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Definition of the disease: Malignant atrophic papulosis (MAP), described independently by Köhlmeier and Degos
et al., is a rare, chronic, thrombo-obliterative vasculopathy characterized by papular skin lesions with central
porcelain-white atrophy and surrounding teleangiectatic rim.
Epidemiology: Less than 200 cases have been described in the literature. The first manifestation of MAP usually
occurs between the 20th and 50th year of life.
Clinical description: The cutaneous clinical picture is almost pathognomonic. The histology is not consistent but
in most cases it shows a wedge-shaped connective tissue necrosis in the deep corium due to a thrombotic
occlusion of the small arteries. In the systemic variant, manifestations mostly occur at the intestine and central
nervous system.
Etiology: The etiopathogenesis of the disease remains unknown, a genetic predisposition may occur. Vasculitis,
coagulopathy or primary dysfunction of the endothelial cells have been implicated.
Diagnostic methods: Diagnosis is only based on the characteristic skin lesions.
Differrential diagnosis: It depends on the clinical presentation of MAP, but systemic lupus erythematosus and
other connective tissue diseases need to be considered.
Management: No effective treatment exists for the systemic manifestations, while compounds that facilitate blood
perfusion have achieved a partial regression of the skin lesions in single cases.
Prognosis: An apparently idiopathic, monosymptomatic, cutaneous, benign variant and a progressive, visceral one
with approx. 50% lethality within 2–3 years have been reported. Systemic manifestations can develop years after
the occurrence of skin lesions leading to bowel perforation and peritonitis, thrombosis of the cerebral arteries or
massive intracerebral hemorrhage, meningitis, encephalitis, radiculopathy, myelitis.
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The malignant atrophic papulosis (Köhlmeier-Degos di-
sease; MAP) was described by Köhlmeier in 1941 [1]
and documented as a separate entity by Degos et al. one
year later [2]. Although MAP has been known for almost
70 years, its pathomechanism remains still obscure. As a
result no treatment has been proven sufficient enough
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distribution, and reproduction in any mediumIt is a rare disease; until today less than 200 cases have
been described in the literature. The first manifestation
of MAP usually occurs between the 20th and 50th year
of life [3,4], while single cases with MAP in newborns
and children have also been described [5,6]. A genetic
predisposition with an autosomal dominant trait has
been suggested, since there has been reports about more
frequently affected 1st degree relatives [7-9].
The following article presents an overview of MAP as
well as a summary of the proposed theories of disease de-
velopment. The exact knowledge of MAP research history
may lead to new unexplored pathways and eventually tontral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 2 Characteristic lesions with porcelain-white center und
a surrounding erythematous rim on the upper extremities of a
male patient.
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Clinical manifestations
The diagnosis of MAP is based in the majority of the
cases on the pathognomonic skin lesions. They are about
0.5-1 cm large papules with an atrophic porcelain-white
centre and an erythematous, teleangiectatic rim mostly
occurring on the trunk and the upper extremities [4,10]
(Figures 1, 2). The lesions appear initially as small ery-
thematous papules. After a few days the centre sinks and
they start to demonstrate the characteristic morphology.
Palms, soles, scalp and face are rarely involved. On the
other hand, involvement of the internal organs, with
multiple limited infarcts of the intestine and/or the cen-
tral nervous system (CNS) as well as of other organs,
such as the lungs (presenting as pleuritis and/or pericar-
ditis) and the eyes, has also been reported [11-14].
Prognosis
Due to the markedly different prognosis between the ap-
parently idiopathic cutaneous disease and MAP withFigure 1 Cutaneous involvement of Köhlmeier-Degos disease
showing scattered typical lesions on the lower extremities of a
female patient.systemic involvement, the first variant - in contrast to
the latter "malignant" one - has been termed "benign
atrophic papulosis" by some authors [15,16]. However, it
is still unclear if these two forms can be unambiguously
distinguished from each other, since systemic involve-
ment can develop year after the occurrence of the skin
lesions.
The so called "benign" form of the disease is characte-
rized by the typical skin lesions, which persist over years
or lifelong, without involvement of the inner organs
[17]. Several cases have exhibited signs of inheritance,
especially between first-degree relatives [7,9]. The malig-
nant variant is characterized by involvement of the skin
and the inner organs, either occurring simultaneously or
subsequently. The systemic manifestations can be fol-
lowed in many cases by serious complications, namely
bowel perforation and peritonitis as well as thrombosis
of the cerebral arteries or massive cerebral hemorrhage,
meningitis, encephalitis, radiculopathy, myelitis [18]
leading to lethal course in approx. 50% of the patients
within 2 to 3 years. Lung involvement can be followed
by pleuritis and/or pericarditis [10,19,20]. The prognosis
can also be influenced by the extent of these ischemic
complications, which are the determinants of mortality
[2,8,21]. An ocular involvement with affection of the
eyelids, conjuctiva, retina, sclera and the choroid plexus,
as well as the development of diplopia and ophthalmo-
plegia as secondary side effects of the neurologic in-
volvement have also been described [22]. The fact that a
systemic involvement can develop suddenly, years after
the occurrence of skin lesions, makes a regular medical
follow-up of the patients necessary.
Diagnosis
The diagnosis of MAP is a clinical one and can be sup-
ported by the histological findings. The classical his-
tology shows a wedge-shaped connective tissue necrosis,
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the corium [20,23,24]. However, these characteristic fea-
tures cannot be demonstrated in all cases [25]. Harvell
et al. [26] examined in a case report the histology of the
lesions according to the duration of their existence. Early
lesions have shown a superficial and deep perivascular
lymphocytic infiltration, with distinct mucin deposition,
which resembled lupus erythematosus. The fully deve-
loped lesions had more prominent changes in the der-
moepidermal junction, with atrophy of the epidermis
and an area of sclerosis in the papillary dermis. These
characteristics could be compatible with a minimal vari-
ant of lichen sclerosus et atrophicans. The late lesions
showed a wedge-shaped necrosis, sparse lymphocytes
and markedly less mucin deposition in comparison to
the early and fully developed lesions (Figure 3).
No specific alterations of laboratory parameters - if
any - have been reported [10] and no markers exist,
which could verify the diagnosis. However, a relative
large percentage of the patients has been described to
present defects of blood coagulation.
Etiology and pathogenesis
The etiology of MAP remains unexplained. There is a
whole series of hypotheses but none of them could be
proven yet. The 3 most reasonable suggested hypotheses
about the pathophysiology of the disease are vasculitis,
coagulopathy and primary dysfunction of the endothelial
cells [27]. Although heterogeneous the aforementioned
etiological suggestions are not necessarily mutually ex-
clusive. The simultaneous presence of various factors
creating the appropriate conditions for the development
of thrombosis should be considered.
Malignant atrophic papulosis as vasculitis
Soter et al. [24] have proposed that inflammation of the
vessels could act as a trigger factor for the development
of MAP. This inflammation was evaluated as an initial
stadium of the disease, as in the histological samples ofFigure 3 Biopsy from skin lesions showing a wedge-shaped necrosis,
disarrangement of the collagen fibers in the corium.patients with MAP did not always demonstrate inflam-
matory cells. Su et al. [28] described a “lymphocyte-
associated necrotic vasculitis” as the most prominent
cutaneous feature of the skin lesions. In addition, they
observed an analogy between the disseminated vasculitic
process of the disease and the skin lesions of some
patients with lupus erythematosus, which seemed simi-
lar. Currently, Magro et al. [29] have reported prominent
C5b-9 deposits in skin, gastrointestinal tract and brain
vessels of 4 patients with MAP, who have died from the
disease. All cases had evidence of high expression of
interferon-α (based on tissue expression of MXA, a type
I interferon-inducible protein), endothelial tubuloreticu-
lar inclusions, and an interferon gene signature in pe-
ripheral blood mononuclear cells. The MXA expression
paralleled the pattern of C5b-9 deposition.
Degos disease as coagulopathy
A thrombus deep in the dermis (stratum reticulare) is the
primary event in MAP. The reduction of the blood flow
and the resulting damage of the endothelial cells lead to
deposition of mucin and aggregation of mononuclear cells
[30]. Several authors have observed fibrinolytic dysfunc-
tion in selected patients [21,31-33]. Stahl et al. [34] and
Drucker [35] have described single patients who showed
an increased platelet aggregation in vivo. Both patients
responded very well on the treatment with platelet aggre-
gation inhibitors, namely aspirin and dipyridamole. Black
et al. [36] observed a complete loss of fibrinolysis around
the small blood vessels, in the centre of old and new
papules in skin lesions of patients with MAP. Vazquez-
Doval et al. [4] and Olmos et al. [18] described an increase
of the activity of plasminogen activator inhibitor-1, while
Paramo et al. [31] found that the serum level of plasmino-
gen was decreased in a patient with MAP. Alternatively,
Englert et al. [37], Mauad et al. [38] and Farell et al. [39]
treated single patients with positive lupus anticoagulant.
In addition to that, Yoshikawa et al. [40] have described a
persistent increase of the thrombin-antithrombin IIIarteriolar obliteration, epidermal atrophy, hyperkeratosis and
Theodoridis et al. Orphanet Journal of Rare Diseases 2013, 8:10 Page 4 of 5
http://www.ojrd.com/content/8/1/10complex and of plasmin-α-2 plasmin inhibitor complex.
All these observations may provide an explanation for the
pathogenesis of MAP. Currently, Meephansan et al. [41]
observed strong staining of the infiltrating inflammatory
cells in the perivascular, intravascular, and perineural areas
in tissue samples from 2 MAP patients with stromal
cell–derived factor (SDF)-1/CXCL12, which is secreted by
bone-marrow stromal and endothelial cells, activates mega-
karyocyte precursors, and costimulates platelet activation.
MAP as primary or secondary dysfunction of the
endothelial cells
Tribble et al. [42] supposed that an abnormal swelling
and proliferation of the vascular endothelium could trig-
ger cutaneous, intestinal and central nervous system
thrombosis. Howard and Nishida [43,44] observed
tubulo-reticular aggregates in the endothelial cells with
the help of electron microscopy. Therefore, a viral or bac-
terial infection could act as a cause for the endothelial
changes [43-45]. Other authors showed intracytoplas-
mic paramyxovirus-like inclusions in electron micros-
copy of skin specimens from patients with MAP
[18,35]. However, no proof of paramyxovirus-DNA in
skin biopsies of patients has been provided via poly-
merase chain reaction [31].
Management
There is no uniformly effective therapy for MAP. Efforts
with fibrinolytic and immunosuppressive therapeutic regi-
mens like cyclosporine A, azathioprine, cyclophosphamide
and corticosteroids have been mostly unsuccessful. Fur-
thermore, there have been reported cases where MAP
worsened during immunosupression [7,46]. Explorative
treatment with eculizumab could not prevent the develop-
ment or progression of systemic manifestations (personal
communications), despite its reported initial effectiveness
on skin and intestinal lesions [47,48]. Other therapeutic
efforts with anticoagulants and compounds that facilitate
blood perfusion, such as acetylosalicylic acid (aspirin),
pentoxifylline, dipyridamole, ticlodipine and heparin, have
achieved a partial regression of the skin lesions in single
cases [4,11,28,34,39,49,50]. Therefore, these agents can
be used as a first therapeutic approach on a newly
diagnosed patient with MAP. Subcutaneous treprosti-
nil has currently been tested successfully in a case
with eculizumab-resistant MAP with intestinal and
CNS manifestations (Dr. Lee S. Shapiro, Albany, NY,
personal communication).
Since every diagnosed MAP case can potentially de-
velop into the systemic, life-threatening variant, an
annual follow-up is mandatory. This should include a
clinical inspection of the skin combined with additional
examinations, such as brain magnetic resonance tomog-
raphy, gastroscopy and colonoscopy, as well as X-ray ofthe chest and abdominal ultrasound in order to assess
the long-term prognosis.Conclusion
MAP is a rare and potentially life-threatening disease. The
prognosis highly depends on the development of systemic
involvement. Most of the lethal courses are due to bowel
perforation or CNS lesions and their consequences. The
probability of a benign course increases with the duration
of monosymptomatic cutaneous disease.
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